Bristol-Myers Squibb (NY:BMY)

58.81 -2.34 (-3.83%)

Official Closing Price Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

93 94 Next >

This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

November 12, 2024

Via Benzinga

Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock ↗

November 12, 2024

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, predicting significant stock outperformance.

Via Benzinga

What's Going On With Bristol-Myers Squibb Shares Monday? ↗

November 11, 2024

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie Inc (NYSE:ABBV) announced that its Phase 2 EMPOWER trials did not meet...

Via Benzinga

Dow, S&P 500 On Track For Milestone Closes ↗

November 11, 2024

Wall Street is extending its post-election rally into a new week.

Via Talk Markets

Topics Stocks

AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated ↗

November 11, 2024

AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company's broader drug pipeline.

Via Benzinga

How Is The Market Feeling About Bristol-Myers Squibb? ↗

November 04, 2024

Via Benzinga

Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal ↗

November 11, 2024

Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the company.

Via Benzinga

AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges ↗

November 11, 2024

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for next steps.

Via Benzinga

MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday ↗

November 11, 2024

Via Benzinga

Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails ↗

November 11, 2024

AbbVie stock also tumbled after its experimental schizophrenia treatment failed in two Phase 2 studies.

Via Investor's Business Daily

Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024

November 11, 2024

From Bristol Myers Squibb

Via Business Wire

MarketBeat Week in Review – 11/4 - 11/8

November 09, 2024

Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts

Via MarketBeat

Topics Economy Government

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks ↗

November 08, 2024

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and...

Via Benzinga

Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast ↗

November 06, 2024

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the consensus of $4.12 billion.

Via Benzinga

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

November 05, 2024

From Bristol Myers Squibb

Via Business Wire

Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings

November 05, 2024

After strong earnings reports, Merck may be a better choice than Bristol-Meyers in the short term - but both may present a challenge for buy-and-hold investors.

Via MarketBeat

Topics Intellectual Property

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo ↗

November 04, 2024

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results.

Via Benzinga

Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade ↗

November 01, 2024

On Friday, Bristol Myers Squibb stock earned an upgrade to its Relative Strength (RS) Rating, from 62 to 79.

Via Investor's Business Daily

Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious ↗

November 01, 2024

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a robust neuropsych pipeline.

Via Benzinga

Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024

October 31, 2024

From Bristol Myers Squibb

Via Business Wire

Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗

November 01, 2024

The major indexes declined, but haven't fallen apart.

Via Investor's Business Daily

Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript ↗

October 31, 2024

BMY earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit ↗

October 31, 2024

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis. Adjusted EPS of $1.80 beat estimates.

Via Benzinga

Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday? ↗

October 31, 2024

Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months.

Via Benzinga

Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance ↗

October 31, 2024

The pharma giant has been trading tightly in recent weeks.

Via Investor's Business Daily

Bristol Myers Squibb Reports Third Quarter Financial Results for 2024

October 31, 2024

From Bristol Myers Squibb

Via Business Wire

Markets Give Back Gains As Hovering Continues ↗

October 30, 2024

Market indexes could not hold onto earlier gains this afternoon, and all closed near session lows. The moves were mild, though — as we’ve stated in this space previously, the big news the market is...

Via Talk Markets

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗

October 30, 2024

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Via Benzinga

Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy ↗

October 30, 2024

Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.

Via Benzinga

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024

October 28, 2024

From Bristol Myers Squibb

Via Business Wire

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

93 94 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.